REBECCA LANDRY: Open Payments
NPI 1316537525 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,099 in 95 payments from 15 companies in 2025. Trend: 2023 $1,676 · 2024 $1,567 · 2025 $2,099
Food & beverage: $2,099
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $283 |
| Madrigal Pharmaceuticals | 7 | $256 |
| Janssen Biotech, Inc. | 11 | $218 |
| Ardelyx, Inc. | 9 | $212 |
| Lilly USA, LLC | 9 | $185 |
| Celltrion USA Inc. | 7 | $141 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| Ipsen Biopharmaceuticals, Inc | 3 | $72 |
Products named: ENTYVIO, REZDIFFRA, TREMFYA, IBSRELA, RINVOQ, OMVOH, VEGZELMA, DUPIXENT.
Industry payments across TX — which companies pay providers there.
